The Eurasian Journal of Medicine
Letter to the Editor

47D11 Antibody-Engineered Exosomes for Targeted Delivery of Remdesivir in Patients with COVID-19: Dream or Principle? (A Critical Editorial Study)


Zanjan University of Medical Sciences (ZUMS) Faculty of Medicine, Zanjan, Iran


Department of Immunology, Zanjan University of Medical Sciences (ZUMS) Faculty of Medicine, Zanjan, Iran


Immunotherapy Research & Technology Group, Zanjan University of Medical Sciences, Zanjan (ZUMS), Iran


Department of Medical Biology, Ankara Yıldırım Beyazıt University Faculty of Medicine, Ankara, Turkey


Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research, Network (USERN), Tehran, Iran

Eurasian J Med 2022; 54: 310-312
DOI: 10.5152/eurasianjmed.2022.21116
Read: 1005 Downloads: 418 Published: 10 August 2022

Along with the high transmission rate of coronavirus disease 2019 infection in the last few months, the morbidity and mortality rate of coronavirus disease 2019 has been increased among critically-ill patients, especially the elderly or the ones with immunodeficiencies. So, there is an urgent need to develop more effective therapeutic agents through immunopathophysiological and immunotherapeutic-based strategies for these patients. Here, we hypothesize that mixing S1b-RBD-expressing mesenchymal stem cell-derived exosomes (which have been previously enriched with Remdesivir) with 47D11 antibody, can promisingly guarantee effective transferring of those targeted exosomes to the targeted microenvironment of coronavirus disease 2019 infection. In addition, it can induce their immunomodulatory properties, and anti-viral features, refraining from entrance of severe acute respiratory syndrome-related coronavirus-2 to angiotensin-converting enzyme 2-expressing cells.

Cite this article as: Daneshi N, Esmaeilzadeh A, Bahmaie, N. 47D11 antibody-engineered exosomes for targeted delivery of remdesivir in patients with COVID-19: Dream or principle? (A critical editorial study). Eurasian J Med., 2022;54(3):310-312.

EISSN 1308-8742